LUSTER of differentiation 44 (CD44, Hermes-1, H-CAM) is a broadly distributed polymorphous family of cell membrane glycoproteins involved in cell-cell and cell-matrix adhesive interactions, which was initially described as the homing receptor of lymphocytes. 5, 9, 12, 31, 35, 36, 44 Various functions have been attributed to the CD44 molecule: 1) development and differentiation of T and B cells; 2) activation molecule increased on the cell surface as a response to antigen stimulation; and 3) adhesion molecule involved in the heterotypical lymphocyte-endothelial cell-cell interaction, which mediates lymphocyte extravasation from blood into homing lymphoid organs.
purely structural role for the membrane proximal extracellular domain of the CD44 molecule. 38 Furthermore, analysis of recent data has proven the role of CD44 in neoplasia. When CD44 molecules are transfected into melanoma or lymphoma cells, tumorigenicity is increased, and this is ECM-binding dependent. 4, 40 Within the nervous system, CD44 molecules have been localized on normal glial cells, 43 Schwann cells, and glial tumors, in some of which CD44 is overexpressed; 25 however, it has not been localized on neurons or oligodendrocytes. 11, 32 The expression of CD44 appears to be maintained during tumorigenesis. 3, 8 This has prompted many investigations aimed at examining whether this molecule plays an important role in central nervous system neoplastic development, thus focusing on invasion and metastasis. Interestingly, a pan-CD44 antibody that recognizes all CD44 isoforms has been shown to block glioma cell invasiveness in vitro. 30 In the present investigations we have endeavored to address an important biological property of GBMs, namely their highly invasive behavior, which is a major factor in determining a lower treatment success rate than might be expected in tumors that almost never metastasize. In this process, the CD44 adhesion molecule is thought to have an important role in regulating the adhesive and locomotor properties of malignant glioma cells because, during invasion, homotypical adhesion is reduced with a concomitant increase in heterotypical adhesion. 37 Analysis of our data demonstrates, for the first time, that local treatment with an anti-CD44s mAb can effectively inhibit glioma invasion, thus blocking tumor growth. Continuous delivery and long-term extracellular persistence of anti-CD44 antibodies efficiently disrupted glioma invasiveness and, therefore, tumor progression. The model used in this study is artificial, but although the specific intratumorally injected anti-CD44s mAb most likely reacted with CD44s, epitopes constitutively expressed on normal nonneoplastically transformed glial cells as well, 21 it did not affect the rats. On the contrary, treated animals developed less tumor-induced cachexia compared with control animals, thus suggesting a protective effect of the treatment.
Materials and Methods

Tumor Cell Culture
The rat GBM cell line C6 was cultured in flasks in DMEM and supplemented with 10% fetal calf serum, 100 g/ml streptomycin, and 100 U/ml penicillin. Cells were routinely kept in culture in a standard humidified incubator at 37˚C in a 5% carbon dioxide/95% air atmosphere. At subconfluence, the culture medium was discarded, the cells were washed once in sterile Dulbecco's PBS and harvested by trypsinization for 5 minutes at 37˚C, and the cell suspension was collected in 50-ml tubes. After centrifugation for 10 minutes at 1400 rpm and 4˚C, the cells were resuspended in 6 ml complete DMEM. Cell density and viability were determined by standard hemocytometric counting of trypan blue-excluding cells in a hemocytometer by using an inverted microscope.
Preparation of Coverslips
Round 18-mm-diameter glass coverslips and round 25-mm-diameter coarse filter papers layered alternately to form a stack were introduced into a 50-ml tube. The stack was thoroughly washed in 100% ethanol and then air dried. The stack was immersed in 2 N NaOH solution and incubated at room temperature overnight. The following day, the NaOH solution was discarded, and the stack was rinsed thoroughly with tap water. The stack was immersed in PBS and incubated at room temperature overnight. This procedure removes residual acidity on the surface of glass coverslips, which improves adherence of cultured cells. The stack was again rinsed extensively with tap water and then in double-distilled water and finally immersed in 100% ethanol. After complete air drying, the coverslips were gamma-irradiated at 200 Gy and aseptically distributed into 12-well plates. Coverslips were coated overnight with 1 g/cm 2 laminin in sterile PBS. After removing the coating solution, the 12-well plates were kept sterile in the incubator.
Culture of Cells on Coverslips
After counting and determining viability, the cells were diluted in complete DMEM at a final concentration of 10 6 /ml and kept on ice until inoculation. The cells were inoculated at 5 ϫ 10 4 /well onto the previously prepared glass coverslips and kept in culture for 3 days. The culture medium was then discarded, and the coverslips were rinsed three times with PBS to remove culture medium completely. Finally, the coverslips were fixed in a 1:1 methanol/acetone mixture at Ϫ20˚C for 10 minutes. After discarding the fixative mixture, the coverslips were air dried overnight.
Preparation of Antibodies
Mouse anti-CD44s mAb and an isotype control IgG 1 were dialyzed for 24 hours at 4˚C to remove cytotoxic NaN 3 (sodium azide) ions. Dialysis was performed in 1-kD disposable dialyzers against sterile PBS. Antibody solutions were collected, and protein concentrations were measured spectrophotometrically by absorbance at 280 nm. After adjusting the concentration of both antibodies at 0.64 g/l, 50-l aliquots were frozen and kept at Ϫ20˚C until use.
Cytotoxicity Assay
The putative cytotoxic effect of anti-CD44s mAb and isotype control IgG 1 was assessed using a nonradioactive cell proliferation and cytotoxicity assay. After counting and determining viability, 2 ϫ 10 3 cells/well were incubated in a 96-well plate in complete DMEM, in the presence of 20 l/well dye substrate, according to the manufacturer's instructions. Anti-CD44s mAb or isotype control IgG 1 was added to the wells as follows: 2, 8, or 20 g/well and further incubated for 5 hours. Controls were incubated under the same conditions but in the absence of antibodies. Finally, absorbance was measured at 450 nm with 620 nm as a reference. Assays were performed in triplicate.
Adhesion Assay
Sterile glass coverslips were coated overnight with 1 g/cm 2 laminin or fibronectin or with 5 g/cm 2 collagen, in sterile PBS. Coating solutions were removed, and the 12-well plates were kept sterile in the incubator. Cells were inoculated at 5 ϫ 10 4 /well onto glass coverslips and kept in culture for 18 hours (initial adhesion and proliferation). Thereafter, anti-CD44s mAb or isotype control IgG 1 was added to the wells as follows: 1.28, 2.56, 5.12, 7.68, 10.24, and 12.8 g/well. The cells were cultured for another 18 hours in the presence of antibodies. Control cells were cultured under the same conditions but were not treated with antibodies. Culture medium was discarded and coverslips fixed as described. Assays were performed in triplicate.
Surgical Procedure
Fifty-five congenitally athymic, adult male and female nude rats weighing 158 to 183 g each were used. Rats were kept initially in groups of three, housed in sterile cages, and given free access to food and water (according to federal and government regulations). Anesthesia was induced by intraperitoneal administration of 0.05 ml 2% Rompun supplemented with 0.15 ml 10% Ketanest. Stereotactic surgery was performed under sterile conditions by using a stellar stereotactic instrument for rats and a technique previously described. 37 Briefly, a 1.5-mm burr hole was drilled over the right frontal lobe of the rat by using the following stereotactic coordinates: bregma 3 mm, lateral 2 mm, and interaural 7 mm. 34 After re-flection of the periosteum, a polyethylene-silicone device (4-mm cross diameter, 2-mm thickness) was affixed to the skull by using Histoacryl, to be used for later local intracerebral injections in the treated rats to control accurately the depth of instilled solutions while minimizing tissue damage. In the center of the device, a thin polyethylene-silicone tube (outer cross diameter 1.2 mm) was welded to protrude 2 mm intracortically into the rat brain. Cells to be injected into the rat brain were prepared as previously described and finally resuspended in sterile PBS (instead of complete DMEM). Initially, a 50-l suspension containing 5 ϫ 10 4 cells was injected over 1 minute through a syringe that had been adapted to the extracranial aperture of the device. Afterward, the opening of the device was sealed with a droplet of bone wax to prevent reflux, and the skin was sutured. After surgery, the rats were kept in individual cages. They were monitored for hydration and nutritional status on a daily basis throughout the study. Eleven groups of five rats each were randomly formed at the start of the experimental phase (Table 1) .
Treatment Protocol
To determine growth kinetics of brain tumors in the absence of treatment, rats were killed on Days 7, 14, and 21 following transplantation of cells (Groups K1, K2, and K3, respectively; Table 1 ). One week posttransplantation of cells, rats in three other groups were treated with anti-CD44s mAb (Group T1), sham treated with isotype control IgG 1 (Group T2), or sham treated with PBS (Group T3), respectively (Table 1) ; three treatments were given on Days 7, 10, and 12, respectively. Anti-CD44s mAb or isotype control IgG 1 was applied at 32 g/50 l/dose, and PBS was applied at 50 l/ dose. All treated rats were killed on Day 14. The effect of the anesthetic and treatment on rats was assessed by implanting polyethylene-silicone devices in the absence of C6 cells and by induction of anesthesia as well as by performing anti-CD44s mAb or isotype control IgG 1 instillations at the same timepoints as in the C6-tumor transplanted rats (Groups A1 and A2; Table 1 ). On Days 7, 14, or 21 following the start of the experimental phase, control rats (Groups C1, C2, and C3, respectively; Table 1 ) were simply monitored for food and water intake in the absence of anesthetic, tumor transplantation, and treatment.
Preparation of Histological Samples
For preparation of the brains, a thin butterfly catheter was sutured in the abdominal aorta, and the inferior vena cava was opened. The rats were initially perfused with 60 ml PBS supplemented with 30,000 U heparin. Thereafter, the rats were perfused with 60 ml buffered formalin solution for in situ fixation. Brains were removed from the skulls, dissected under the view of a stereomicroscope at a total magnification of ϫ 6.3 to ϫ 40, and cut into 3-mm-thick slices, starting from the initial canal of transplantation. Brain slices were further fixed in buffered formalin for another 2 days. Brain slices were dehydrated using 50, 70, 90, and 100% ethanol. After treatment with acetone, the slices were embedded in paraffin (56-58˚C melting point), and 7-m sections were cut. For each rat, five separate samples were analyzed. Routine histological examination of consecutive slices was performed with hematoxylin and eosin staining.
Flow Cytometric Analysis
To determine the binding saturation of the anti-CD44s mAb, cells were grown as described, harvested at subconfluence by trypsinization, centrifuged, and resuspended in fresh complete cell culture medium. The cells were kept for 45 minutes in the tissue-culture incubator. After counting, 10 5 cells per sample were first washed with ice-cold PBS 1%-BSA, centrifuged, and the pellet was resuspended in 100 l PBS 1%-BSA containing anti-CD44s mAb (1, 2, or 5 g) or in 100 l PBS 1%-BSA containing isotype control IgG 1 at the same concentrations. After 30 minutes of incubation on ice, the cells were washed in PBS 1%-BSA and centrifuged, and the pellet was resuspended in 100 l PBS 1%-BSA containing 2 g FITC goat anti-mouse F(abЈ) 2 . After incubation on ice for 30 minutes, the cells were washed in PBS 1%-BSA and centrifuged, and the pellet was fixed with 500 l 1% paraformaldehyde. Fluorescence intensity among 5000 cell events was determined by flow cytometric analysis by using an analyzer equipped with an air-cooled argon ion laser (emitting at 488 nm, 280 V, 15 mW) with a standard optical configuration. Forward-angle and side-scatter light signals were collected for gating purposes. Fluorescence intensity was measured using a 530 Ϯ 15-nm (SD) bandpass filter that gives an optimum detection for FITC.
Immunocytochemical and Immunohistochemical Procedures
For all immunocytochemical staining procedures, fixed cells on glass coverslips were first rehydrated in PBS for 10 minutes at room temperature. To detect the presence of CD44s, cells were incubated with 5 g/600 l/well anti-CD44s mAb in PBS 1%-BSA for 1 hour at room temperature. The cells were rinsed twice with PBS and incubated with 5 g/600 l/well FITC goat anti-mouse F(abЈ) 2 secondary antibody in PBS 1%-BSA for 1 hour at room temperature in the dark. The cells were rinsed twice with PBS and then incubated with 3 g/600 l/well RNAse A in PBS for 30 minutes at 37˚C to remove RNAs completely. After rinsing twice with PBS, cells were stained with 2 g/600 l/well propidium iodide in PBS for 30 minutes at room temperature in the dark. After rinsing twice with PBS and once with double-distilled water, coverslips were mounted cellside down onto black-mask single-circle cytoslides by using 15 of l mounting medium. After 15 minutes air drying at room temperature in the dark, the mounted coverslips were sealed with 100 l Permount. Mounted specimens were analyzed using an inverted confocal laser scanning microscope at ϫ 100 magnification (oil immersion objective) equipped with an appropriate fluorescence filter set for simultaneous double excitation (488/568 nm). Control staining was performed using the isotype control IgG 1 as the primary antibody and the F(abЈ) 2 antibody as the secondary antibody.
To assess the inhibition of adhesion, cells were incubated with 5 g/600 l/well antivimentin in PBS 1%-BSA for 1 hour at room temperature. Cells were rinsed twice with PBS and incubated with 5 g/600 l/well Cy3 goat anti-mouse F(abЈ) 2 secondary antibody in PBS 1%-BSA for 1 hour at room temperature in the dark. Cells were rinsed twice with PBS, the nuclei were counterstained with 2 g/600 l/well 4Ј,6-diamidino-2-phenylindole in PBS, and the coverslips were mounted as described. Mounted specimens were analyzed at ϫ 20 magnification by using an upright microscope, and cell bodies were counted over the entire surface of each coverslip.
For all immunohistochemical staining procedures, tissue samples were deparaffinized and rehydrated as for routine histological analysis. To detect the presence of CD44s, samples were first antigen retrieved according to a standard protocol. Briefly, samples were boiled in a microwave oven at 800 W power in 0.01 M trisodium citrate monohydrate buffer, pH 6, two times for 5 minutes. After * There were five rats in each group. In pair-tested groups, except for A1/A2 and C1/C2/C3, there were statistically significant differences (p Ͻ 0.0001; see Statistical Analysis).
cooling, the samples were extensively rinsed with PBS and immunostained for CD44s; the nuclei were counterstained and mounted as described. Mounted specimens were analyzed using the inverted confocal laser scanning microscope at ϫ 100 magnification (oil immersion objective).
Morphometrical Analysis and Quantification
For morphometrical analysis of the tumor samples we used a technique previously described. 37 Briefly, consecutive slices, cut at 7 m each, were evaluated microscopically to detect the greatest planar extension of the tumor. A charge-coupled device color camera, adapted to a stereomicroscope, was used to scan hematoxylin and eosin-stained brain slices at a total magnification of ϫ 6.3. The software used was Autoscope/Autoscale. Tumor and brain surfaces were traced in square millimeters after previous calibration of the system by using a standard micron slide. Tumor growth was traced as the quotient: tumor surface (mm 2 )/brain surface (mm 2 ) ϫ 100.
Statistical Analysis
Statistical analysis was performed by an investigator (H.H.) blinded to the experiments who used a standard computer software package. The variables defined were the percentage of tumor area and body weight. Analysis of variance was used to compare differences in tumor progression and body weight among the different groups formed (Table 1) . We compared treated rats (Groups T1, T2, and T3), control rats (Groups C1, C2, and C3), untreated rats (Groups K1, K2, K3), and anesthesia-treated control rats (Groups A1 and A2). Data were pooled from all rats within the same group. For each variable, t-tests (least-significant difference) were performed, with the least-significant difference equal to 0.2344. Statistical significance was set at a probability value less than 0.05.
Sources of Supplies and Equipment
The GBM cell line C6 (CLL-107) was purchased from American Type Culture Collection (Rockville, MD) and cultured in T75 culture flasks obtained from Becton Dickinson (Bedford, MA). Gibco BRL (Gaithesburg, MD) provided the DMEM, fetal calf serum, streptomycin, and penicillin.
Cell density and viability were determined by hemocytometric counting with trypan blue-excluding cells obtained from Sigma Chemical Co. (St. Louis, MO) in a Reichert hemocytometer (Fisher Scientific, Springfield, NJ) and analyzed with the aid of an Axioplan microscope acquired from Carl Zeiss (Jena-Göttingen, Germany).
We obtained the mouse anti-CD44s mAb, the isotype control IgG 1 , the disposable dialyzers, and the RNAse A from Sigma Chemical Co. The nonradioactive cell proliferation and cytotoxicity assay (model EZ4U) was obtained from Biomedica (Vienna, Austria). The nude rats (Nznu The centrifuge (model RT7) was manufactured by Sorvall Products, L.P. (Newtown, CT). The spectrophotometer used to measure protein concentrations is made by Hitachi Instruments, Inc. (Danbury, CT). In the cytotoxicity assays, absorbance was measured using the Microplate Reader, which was obtained from Bio-Rad (Hercules, CA). Fluorescence intensity was measured using an analyzer (model EPICS Profile II) purchased from Coulter Corporation (Hialeah, FL). The confocal laser scanning miscoscope was acquired from Leica Lasertechnik (Heidelburg, Germany). The charge-coupled device color camera (Sony GmbH, Broadcast and Communication, Cologne, Germany) was adapted to fit a stereomicroscope, which was acquired from Wild Leitz (Heerbrugg, Switzerland). The software (Autoscope/Autoscale) used in the morphometric analysis and quantification was obtained from Digithurst (Nüremberg, Germany), and the computer software package (model SPSS/PC+ Version 7.0) used in the statistical analysis was obtained from SPSS International BV (Gorinchem, The Netherlands).
Results
Confocal Laser Scanning Microscopy
Immunodetection of CD44s on cell membranes in vitro as well as within intracerebral tumors showed strong expression of the antigen (Fig. 1a and b) . Membrane distribution was homogeneous-that is, there was no clustering of stronger or weaker CD44-expressing cells. Expression of CD44s in intracerebral tumors was similar on Days 7, 14, and 21 following initial transplantation.
Flow Cytometric Analysis
Detection of CD44s on cell membranes in which 1, 2, or 5 g anti-CD44s mAb for staining 5 ϫ 10 5 cells was used showed that 1 g mAb was sufficient to saturate the binding capacity of the ligand (Fig. 1c) . The relative fluorescence intensity of unlabeled cells (autofluorescence) was 0.39; cells incubated with isotype control IgG 1 (1 g) showed a relative fluorescence intensity of 0.42, and cells incubated with anti-CD44s mAb (1 g) showed a relative fluorescence intensity of 11.94. Anti-CD44s mAb at 2 or 5 g showed similar results (Fig. 1d) .
Disruption of C6 GBM Haptotaxis in Vitro
Inhibition of cell adhesion by anti-CD44s mAb to the precoated coverslips was maximum at 12.8 g/well and similar for all three components of the ECM used, that is, laminin, fibronectin, and collagen (Fig. 2b) . No inhibition of cell adhesion to the coverslips could be detected in the case of incubation of cells with the same concentrations of isotype control IgG 1 , even at the highest dose of 12.8 g/ well (Fig. 2a) .
After 18 hours of cell culture in the presence of graded concentrations of anti-CD44s mAb, inhibition of adhesion scored 0% detached cells at 1.28 g/well or 2.56 g/well. At 5.12 g/well, 11 Ϯ 2.1% (SD) of the cells were detached from the coverslip, compared with the controls. At 7.68 g/well or 10.24 g/well, 31 Ϯ 3.1% (SD) to 59 Ϯ 2.9% (SD) of the cells were detached from the coverslips, respectively. At 12.8 g/well, 94 Ϯ 2.7% (SD) of the cells were detached from the coverslip, compared with the controls.
Disruption of C6 GBM Haptotaxis in Vivo
Intracerebral tumors grew as solid, highly invasive masses ( Fig. 2c) with blurred delineation against host brain tissue. Tumor invasion of the host brain occurred mainly by diffuse infiltration of the white matter and to a much lesser extent by guided spread along brain blood vessels. Tumor progression in the growth-kinetics groups, K1, K2, and K3 (7, 14, and 21 days following initial transplantation in absence of treatment; Table 1 ), showed typi-cal exponential growth: 1.3 Ϯ 0.3% (SD) on Day 7, 6.3 Ϯ 1.1% (SD) on Day 14, and 19.9 Ϯ 0.9% (SD) on Day 21 (Fig. 3c) . The rats in Group T1, which were treated with three successive doses (32 g each) of anti-CD44s mAb on Days 7, 10, and 12 following initial transplantation (Table 1) , harbored significantly smaller tumors (3.6 Ϯ 0.4% [SD]) on Day 14 (Fig. 3c) Fig. 3c ). However, these rats harbored tumors comparable to those of the growthkinetics group, K3 (19.9 Ϯ 0.9% [SD]), which were killed on Day 21 following initial transplantation (Fig. 3c) . In treatment control Groups A1 (anti-CD44s mAb treated) and A2 (isotype control IgG 1 treated), in which rats were monitored just for the effect of the anesthetic and repeated instillations in the absence of tumor (Table 1) , only small cavities (glial scars) were measured (0.3 Ϯ 0.07% and 0.3 Ϯ 0.06% [SD], respectively), which corresponded to the implantation site of the device (Fig. 3c) .
Cytotoxicity Assay
Even at the highest antibody concentration of 20 g/ well for both anti-CD44s mAb and isotype control IgG 1 , no cytotoxic effect was detected, compared with controls incubated under the same conditions but without antibodies (Fig. 3a) .
Effect of Treatment on Rat Weight
In the daily monitoring of hydration and nutritional status of the rats, significant differences between groups were revealed. Tumor progression in the growth-kinetics groups, K1, K2, and K3 (7, 14, and 21 days following initial transplantation in absence of treatment; Table 1 ), correlated with a decrease in body weight: 168 Ϯ 3.2 g (SD) on Day 7, 137 Ϯ 4.7 g (SD) on Day 14, and 83 Ϯ 2.7 g (SD) on Day 21 (Fig. 3d) . Rats in Group T1, which were treated with three successive doses (32 g each) of anti- Fig. 3d ). However, these rats presented with body weights comparable to those of rats in the growth-kinetics Group K3 (83 Ϯ 2.7 g), which were killed on Day 21 following initial transplantation (Fig. 3d) . Similarly, no differences in body weight were observed on Day 14 between the two treatment control groups, A1 (anti-CD44s mAb treated; 176 Ϯ 17.8 g [SD] ) and A2 (isotype control IgG 1 treated; 176 Ϯ 20.4 g [SD]), in which rats were monitored just for the effect of anesthetic and repeated instillations in the absence of tumor (Table 1 and Fig. 3d) . However, these rats presented with body weights comparable to those of the control group, C2 (210 Ϯ 23.5 g [SD]), which were monitored on the same day (Day 14; Fig. 3d ). In the rats in control Groups C1, C2, and C3 (on Days 7, 14, and 21, respectively, following start of the experimental phase), which were monitored just for hydration and nutritional status in the absence of anesthetic, C6 cell transplantation, and treatment (Table 1) (Fig. 3d) .
Discussion
The mechanisms involved in ECM-dependent glioma cell migration are still poorly understood, although there is a strong body of evidence that HA plays a critical role in promoting migration in human gliomas. 6 Invasive behavior of glioma cells mediated by the interaction of HA with CD44s (over)-expressed on their surface was demonstrated in vitro in primary cultures obtained from biopsy material by inhibition of migration and invasion with an anti-CD44s antibody. 6 Similar results were obtained with eight established glioma cell lines. 24 However, there is clear evidence of only partial inhibition of invasion by anti-CD44s antibodies, thus suggesting that HA receptors other than CD44 are likely to be involved in HA-dependent invasion of glioma cells. Statistical significance was set in all tests at a probability value less than 0.05. a: Effect of anti-CD44s mAb and isotype control IgG 1 on proliferation and viability of C6 GBM cells. Assays were performed in triplicate. Note that there is no statistically significant difference between all pair-tested concentrations. b: Disruption of C6 GBM cell haptotaxis (adhesion) to glass coverslips precoated with laminin, fibronectin, or collagen after 18 hours of culture in the presence of graded concentrations of anti-CD44s mAb. The C6 GBM cells were 0% detached at 1.28 g/well or 2.56 g/well; this increased to 11 Ϯ 2.1% at 5.12 g/well, 31 Ϯ 3.1% at 7.68 g/well, 59 Ϯ 2.9% at 10.24 g/well, and 94 Ϯ 2.7% at 12.8 g/well. The C6 GBM cells were 0% detached after incubation with the same concentrations of isotype control IgG 1 , even at the highest dose of 12.8 g/well. Assays were performed in triplicate. Note that all pair-tested concentrations show statistically significant differences (p Ͻ 0.0001). c: Disruption of intracerebral progression (haptotaxis) of C6 GBM by anti-CD44s mAb. Note that there is no difference in tumor progression between the two groups of sham-treated rats (T2 and T3); however, these rats had tumors comparable to those of the rats in the growth-kinetics Group K3 (19.9 Ϯ 0.9%), which were killed on Day 21 after initial transplantation. There were no tumors; only small cavities (glial scars) corresponding to the implantation site of the device were measured in the treatment control groups, A1 and A2 (anti-CD44s mAb 0.3 Ϯ 0.07% and isotype control IgG 1 0.3 Ϯ 0.06%, respectively), in which the rats were monitored just for the effect of anesthesia and repeated instillations in the absence of transplanted C6 GBM cells. The C1, C2, and C3 groups were composed of nontransplanted and nontreated rats. In all pair-tested groups, except for A1/A2 and C1/C2/C3, there were statistically significant differences (p Ͻ 0.0001). Asterisks indicate the main differences. d: Body weight of treated, sham-treated, and control rats. Note that there is no difference in body weight on Day 14 between the two groups of sham-treated rats T2 and T3 (isotype control IgG 1 , 83.4 Ϯ 1.1 g and PBS, 83 Ϯ 2.2 g, respectively). However, these rats presented with body weights comparable to those of the rats in growth-kinetics Group K3 (83 Ϯ 2.7 g), which were killed on Day 21 after initial transplantation. No differences in body weight were observed on Day 14 between the two treatment control Groups A1 and A2 (anti-CD44s mAb [Nil +CD44] 176 Ϯ 17.8 g and isotype control IgG 1 [Nil +IgG] 176 Ϯ 20.4 g, respectively), in which rats were monitored just for the effect of anesthesia and repeated instillations in the absence of transplanted C6 GBM cells. However, these rats presented with body weights comparable to those of control group C2 (Nil; 210 Ϯ 23.5 g), which were monitored on the same day (Day 14). Rats in control Groups C1, C2, and C3 (7, 14 , and 21 days after start of the experimental phase), which were monitored just for hydration and nutritional status in the absence of anesthesia, C6 GBM cell transplantation, and treatment, had a progressive increase in body weight: C1 (7 days, 196.6 Ϯ 29.3 g), C2 (14 days, 210 Ϯ 23.5 g), and C3 (21 days, 225 Ϯ 28.3 g), compared with all other groups. In all pair-tested groups, except for A1/A2 and C1/C2/C3, there were statistically significant differences (p Ͻ 0.0001). Asterisks indicate the main differences. +C6 = K1-K3 groups; +C6 +CD44 = T1 group; +C6 +IgG = T2 group; +C6 +PBS = T3 group; Nil = C1-C3 groups; Nil +CD44 = A1 group; Nil +IgG = A2 group.
HA is not a unique ligand for CD44, other major components of the ECM may participate in glioma cell invasiveness as well. 7, 12, 19, 30 We can infer from our data that interactions between CD44s and its natural ligands (laminin, fibronectin, and collagen) are disrupted by an anti-CD44s mAb. Incubation of C6 GBM cells with anti-CD44s mAb 18 hours following initial adhesion caused a dose-dependent detachment of the cells from the ECM-coated culture surface. Binding saturation of anti-CD44s to the receptor occurred at 1 g, and 18 hours of in vitro incubation with 12.8 g anti-CD44s mAb was sufficient to induce almost complete detachment of C6 GBM cells. This effect was similar for all three ECM components, thus supporting the major role played by CD44s in glioma cell adhesion and invasion. Furthermore, despite the fact that no cytotoxic effect of anti-CD44 mAb was detected, inhibition of adhesion was highly specific, because the matched isotype control IgG 1 showed no effect.
It has been shown that binding of CD44s to HA is dependent on the binding of ankyrin to its cytoplasmic domain, which appears to be regulated by protein kinase Cmediated phosphorylation, palmitylation, and guanosine triphosphate binding. 29 The close association of the cytoplasmic domain of CD44 with actin filaments 17, 18, 22, 26, 41 and the organization of the latter into stress fiber arrays indicate the role played by CD44 in cytoskeletal rearrangement during active glioma cell migration. 16 This correlates with fast brain-tumor progression, as shown in our study. Thus, in addition to participating in cellular adhesion, CD44s may function as a signal-transducing molecule that promotes glioma cells to produce autocrine and paracrine growth factors. Such cytokines are critical for tumor progression, because initial adhesion of tumor cells to the ECM is followed by angiogenesis. 39 Analysis of our data demonstrates that strong expression of CD44s correlated with rapid tumor growth and invasion of host brain tissue. Progression (that is, invasion and growth) of intracerebral C6 tumors was strongly inhibited by only three local instillations of anti-CD44s mAb, which supports the observation that tumor progression is dependent on adhesion to the ECM. In the case of malignant melanoma, interactions between CD44s and its ligands are seemingly critical not only for tumor progression but for metastasis as well, and treatment with an anti-CD44s antibody blocks the latter. 13 Analysis of other findings, on the other hand, demonstrated that treatment of melanoma cells with an anti-CD44s mAb blocking the receptor increased their metastatic ability and adhesiveness. 33 Analysis of our data shows that local treatment of intracerebral C6 tumors, which was begun 1 week following transplantation to allow initial growth and was conducted for 1 additional week, was efficient to stop tumor progression. Therefore, treated tumors reached only approximately half of the total cross-sectional area on Day 14, compared with tumors obtained from untreated or sham-treated animals. This effect is consistent with other findings that show specific blocking of melanoma progression and metastasis by treatment with an antiCD44s antibody. 13 The major difference, besides the cell line used, between the former study and our findings is the fact that anti-CD44s had to be given either on the same day or no later than 3 days after melanoma cell injection to achieve significant inhibition. This discrepancy may be explained by the fact that different clones of melanoma cells differently select for CD44s expression, 13, 32 and melanomas may express particular CD44 splice variants that confer metastatic potential, whereas gliomas do not. Furthermore, this could be one reason why the latter tumors do not metastasize. However, authors of other reports have shown that CD44v is expressed, although at very low levels, in a small fraction of some primary and established glioma cell lines. 8, 21 These observations are of great interest because metastases display, in most cases, a macroand microscopically sharp delineation from the surrounding brain in contrast to gliomas, which diffusely infiltrate brain tissue.
A striking observation made in the present study is that intracerebral tumors obtained in rats from Groups T2 and T3 that were sham treated with either isotype control IgG 1 or PBS progressed significantly faster and thus reached similar areas on Day 14 as those untreated tumors obtained in rats from Group K3 on Day 21. We have previously reported a similar phenomenon in the case of intracerebral transplantation of U-87 GBM, suggesting a cytokine-mediated tumor growth-promoting effect of irrelevant substances (isotype control IgG 1 or PBS). 39 This effect could be explained by the fact that repeated intratumoral instillations may stimulate glioma cells to release higher amounts of autocrine cytokines such as basic fibroblast growth factor. However, treatment of intracerebral C6 tumors with anti-CD44s mAb was highly efficient in inhibiting tumor progression, thus prevailing over growthpromoting side effects.
The glioma model used in the present study is artificial, and the specific anti-CD44s mAb that was intratumorally injected most likely reacted with CD44s epitopes constitutively expressed on normal nonneoplastically transformed glial cells as well. 2, 11, 32 The crossreactivity of the anti-CD44s antibody used in the present study with CD44 isoforms constitutively expressed on neurons, axonal membranes, endothelium, and choroid plexus (that is, CD44v4, CD44v5, CD44v6, and CD44v10) could be excluded by microscopic examination of immunohistochemically stained brain sections. A lack of crossreactivity of anti-CD44s antibodies with CD44 isoforms and, vice versa, of anti-CD44v antibodies with the standard CD44 epitope, has been previously demonstrated. 20 This specificity is explained by steric or conformational obstruction of the various CD44 epitopes depending on the degree of glycosylation. 23, 27 In aggregate, our data can be used to demonstrate that local treatment with an anti-CD44s mAb can efficiently disrupt glioma progression and does not affect the treated rats. On the contrary, treated animals presented with less tumor-induced cachexia than the control rats, thus suggesting a protective effect of the treatment. Although continuous delivery and long-term extracellular persistence of anti-CD44 antibodies effectively disrupted glioma progression, the treatment failed to cure brain tumors. This may be explained by the fact that either the antibody was rapidly degraded within the tumor and tumor environment and/or the tumor could rapidly compensate for treatment by overexpressing CD44. Current studies in our laboratory are aimed at elucidating this phenomenon by using micellary encapsulated phosphorothioated antisense oligodeoxynucleotides to CD44s messenger RNA in glioma cells (G Beutel, et al., unpublished data).
